James B. Breitmeyer - Jan 3, 2024 Form 4 Insider Report for Oncternal Therapeutics, Inc. (ONCT)

Role
Chief Executive Officer, Director
Signature
/s/Chase C. Leavitt, Attorney-in-fact
Stock symbol
ONCT
Transactions as of
Jan 3, 2024
Transactions value $
-$27,504
Form type
4
Date filed
1/5/2024, 04:00 PM
Previous filing
Oct 4, 2023
Next filing
Feb 15, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ONCT Common Stock Tax liability -$25.3K -51K -10.32% $0.50 443K Jan 3, 2024 Direct F1
transaction ONCT Common Stock Tax liability -$2.23K -4.49K -22.53% $0.50 15.4K Jan 3, 2024 By Spouse F1
holding ONCT Common Stock 197K Jan 3, 2024 By Family Trust
holding ONCT Common Stock 733 Jan 3, 2024 By Child
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by the Issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units.